Research programme: recombinant human factor VIII - GTC Biotherapeutics/ProGenetics

Drug Profile

Research programme: recombinant human factor VIII - GTC Biotherapeutics/ProGenetics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ProGenetics
  • Developer ProGenetics; rEVO Biologics
  • Class Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haemophilia A

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
  • 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies
  • 06 Dec 2007 Recombinant human factor VIII, factor IX and fibrinogen licensed to GTC Biotherapeutics in North America, Europe and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top